Pemetrexed
disodium heptahydrate is chemotherapeutic
agent and it falls in the class of anti-metabolites.
It is supplied as a sterile lyophilized
powder for intravenous infusion available
in single-dose vials. Each 100-mg or
500-mg vial of ReliTrexed™ contains
pemetrexed disodium equivalent to 100
mg pemetrexed or 500 mg.
Pemetrexed is indicated in combination
with cisplatin therapy for the initial
treatment of patients with locally advanced
or metastatic nonsquamous non-small
cell lung cancer. It is indicated as
a single-agent for the treatment of
patients with locally advanced or metastatic
nonsquamous non-small cell lung cancer
after prior chemotherapy and in combination
with cisplatin is indicated for the
treatment of patients with malignant
mesothelioma whose disease is unresectable
or who are otherwise are not candidates
for curative surgery.
ReliTrexed is available in 100 and 500
mg vials.
